Alvaro Alvarez Soto(he/him/his)
@alvarezsoto.bsky.social
-Hematology/oncology fellow at UCONN Health.
-Passionate about health equity, global oncology, racial and ethnic disparities, Biomarkers in cancer.
-Passionate about health equity, global oncology, racial and ethnic disparities, Biomarkers in cancer.
In other malignancies, like breast cancer, TP53 is not routinely testing (despite being common).
Reliably testing TP53 in breast cancer with IHC in breast cancer was difficult, but now that we have NGS and circulating tumor cells, should we look into this again?
The answer is absolutely!!!
Reliably testing TP53 in breast cancer with IHC in breast cancer was difficult, but now that we have NGS and circulating tumor cells, should we look into this again?
The answer is absolutely!!!
commong.as
December 28, 2024 at 6:04 PM
In other malignancies, like breast cancer, TP53 is not routinely testing (despite being common).
Reliably testing TP53 in breast cancer with IHC in breast cancer was difficult, but now that we have NGS and circulating tumor cells, should we look into this again?
The answer is absolutely!!!
Reliably testing TP53 in breast cancer with IHC in breast cancer was difficult, but now that we have NGS and circulating tumor cells, should we look into this again?
The answer is absolutely!!!